(Q37354971)

19 August 2017

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome (English)

1 reference

19 August 2017

1 reference

neoadjuvant chemotherapy

1 reference

1 reference

6

van de Vijver MJ

1 reference

19 August 2017

Faneyte IF

1

1 reference

19 August 2017

Schrama JG

2

1 reference

19 August 2017

Peterse JL

3

1 reference

19 August 2017

Remijnse PL

4

1 reference

19 August 2017

Rodenhuis S

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

British Journal of Cancer

19 August 2017

1 reference

19 August 2017

88

1 reference

19 August 2017

3

1 reference

19 August 2017

406-412

1 reference

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Clinical studies of Bcl-2 and treatment benefit in breast cancer patients.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Clinical studies of p53 in treatment and benefit of breast cancer patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Clinical and pathological response to primary chemotherapy in operable breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747533

ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy

2 September 2018

1 reference

12 December 2020

Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP

1 reference

12 December 2020

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer

1 reference

12 December 2020

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18

1 reference

12 December 2020

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

12 December 2020

Effect of surgical removal on the growth and kinetics of residual tumor

1 reference

12 December 2020

The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue

1 reference

12 December 2020

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

12 December 2020

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

12 December 2020

Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer

1 reference

12 December 2020

Effects of chemotherapy on breast cancer tissue

1 reference

12 December 2020

Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

1 reference

12 December 2020

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

12 December 2020

Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers

1 reference

12 December 2020

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study

1 reference

12 December 2020

Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival

1 reference

12 December 2020

Prediction of response to primary chemotherapy for operable breast cancer

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer

1 reference

12 December 2020

Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600749

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

12569384

1 reference